[go: up one dir, main page]

HRP20171999T1 - Novi derivati aminopirimidina - Google Patents

Novi derivati aminopirimidina Download PDF

Info

Publication number
HRP20171999T1
HRP20171999T1 HRP20171999TT HRP20171999T HRP20171999T1 HR P20171999 T1 HRP20171999 T1 HR P20171999T1 HR P20171999T T HRP20171999T T HR P20171999TT HR P20171999 T HRP20171999 T HR P20171999T HR P20171999 T1 HRP20171999 T1 HR P20171999T1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
halogen
hydrogen
cyclopropyl
Prior art date
Application number
HRP20171999TT
Other languages
English (en)
Inventor
Daniela Angst
François GESSIER
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20171999T1 publication Critical patent/HRP20171999T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Claims (14)

1. Spoj, naznačen time, da ima sljedeću Formulu (I), ili njegova farmaceutski prihvatljiva sol: [image] (I) u kojoj, R1 je vodik, C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 je vodik; R5 je vodik ili halogen; ili su R4 i R5 zajedno priključeni te predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R, R’, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil prema potrebi supstituiran sa C1-C6 alkoksi; ili bilo koja dva od R8, R9, R, R’, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom ili C1-C6 alkoksi; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa sljedećima: C1-C6 alkil, C1-C6 alkoksi ili N,N-di-C1-C6 alkilamino; C2-C6 alkinil prema potrebi supstituiran sa sljedećima: C1-C6 alkil ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
2. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; ili su R4 i R5 priključeni zajedno i predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
3. Spoj prema zahtjevu 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
4. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 i R5 su priključeni zajedno i predstavljaju vezu, -CH2-, -CH2-CH2- , -CH=CH-, -CH=CH-CH2-; -CH2-CH=CH-; ili -CH2-CH2-CH2-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
5. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je vodik ili halogen; R3 je vodik ili halogen; R4 i R5 su priključeni zajedno i predstavljaju -CH2-CH2- , ili -CH=CH-; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; ili R12 i bilo koji od R8, R9, R, R’, R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može prema potrebi biti supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
6. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
7. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8 i R9 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 i bilo koji od R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može biti prema potrebi supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkileniloksid prema potrebi supstituiran sa C1-C6 alkilom.
8. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je halogen; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8, R9, R10 i R11 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R i R’ su vodik; R12 je vodik ili C1-C6 alkil prema potrebi supstituiran s halogenom; n je 0 ili 1; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi.
9. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je vodik, ili C1-C6 alkil prema potrebi supstituiran s hidroksi; R2 je fluor; R3 je vodik; R4 je vodik; R5 je halogen; R6 i R7 međusobno neovisno predstavljaju H, C1-C6 alkil prema potrebi supstituiran s hidroksilom, C3-C6 cikloalkil prema potrebi supstituiran s halogenom ili hidroksi, ili halogen; R8 i R9 međusobno neovisno predstavljaju H, ili C1-C6 alkil; R12 i bilo koji od R10 ili R11 zajedno s atomima na koje su vezani, mogu tvoriti 4-, 5-, 6- ili 7-člani azaciklički prsten, pri čemu taj prsten može biti prema potrebi supstituiran sa sljedećima: halogen, cijano, hidroksil, C1-C6 alkil ili C1-C6 alkoksi; n je 0; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi; ili C2-C6 alkinil prema potrebi supstituiran sa C1-C6 alkilom ili C1-C6 alkoksi.
10. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da: R1 je C1-C6 alkil; R2 je fluor; R3 je vodik; R4 je vodik; R5 je fluor; R6 i R7 međusobno neovisno predstavljaju H, C3-C6 cikloalkil ili halogen; R8, R9, R10 i R11 predstavljaju H; R12 je vodik; n je 0; i R13 je C2-C6 alkenil prema potrebi supstituiran sa C1-C6 alkilom.
11. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da : je odabran/a od sljedećih: N-(3-(5-((1-akriloilazetidin-3-il)oksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-((1-(but-2-enoil)azetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-((1-propioloilazetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-((1-(but-2-inoil)azetidin-3-il)oksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-((1-akriloilpiperidin-4-il)oksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilakrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-(2-(N-metilbut-2-enamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilpropiolamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (E)-N-(3-(6-amino-5-(2-(4-metoksi-N-metilbut-2-enamido)etoksi)pirimidin-4-il)-5-fluoro- 2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-metilbut-2-inamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(2-((4-amino-6-(3-(4-ciklopropil-2-fluorobenzamido)-5-fluoro-2-metilfenil)pirimidin-5-il)oksi)etil)-N-metiloksiran-2-karboksamid; N-(2-((4-amino-6-(3-(6-ciklopropil-8-fluoro-1-oksoizokinolin-2(1H)-il)fenil)pirimidin-5-il)oksi)etil)-N-metilakrilamid; N-(3-(5-(2-akrilamidoetoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-etilakrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(2-(N-(2-fluoroetil)akrilamido)etoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-((1-akrilamidociklopropil)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-(2-akrilamidopropoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(but-2-inamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(N-metilakrilamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-(2-(N-metilbut-2-inamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(3-(N-metilakrilamido)propoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-((1-akriloilpirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-((1-(but-2-inoil)pirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-2-(3-(5-((1-akriloilpirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; N-(2-((4-amino-6-(3-(6-ciklopropil-1-okso-3,4-dihidroizokinolin-2(1H)-il)-5-fluoro-2-(hidroksimetil)fenil)pirimidin-5-il)oksi)etil)-N-metilakrilamid; N-(3-(5-(((2S,4R)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4R)-1-(but-2-inoil)-4-metoksipirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; 2-(3-(5-(((2S,4R)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; N-(3-(5-(((2S,4S)-1-akriloil-4-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4S)-1-(but-2-inoil)-4-metoksipirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2S,4R)-1-akriloil-4-fluoropirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(6-amino-5-(((2S,4R)-1-(but-2-inoil)-4-fluoropirolidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-N-(3-(6-amino-5-((1-propioloilazetidin-2-il)metoksi)pirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (S)-2-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-(hidroksimetil)fenil)-6-ciklopropil-3,4-dihidroizokinolin-1(2H)-on; (R)-N-(3-(5-((1-akriloilazetidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; (R)-N-(3-(5-((1-akriloilpiperidin-3-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2R,3S)-1-akriloil-3-metoksipirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; N-(3-(5-(((2S,4R)-1-akriloil-4-cijanopirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid; i N-(3-(5-(((2S,4S)-1-akriloil-4-cijanopirolidin-2-il)metoksi)-6-aminopirimidin-4-il)-5-fluoro-2-metilfenil)-4-ciklopropil-2-fluorobenzamid.
12. Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 11 te jedan ili više farmaceutski prihvatljivih nosača.
13. Kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 11, ili njegove farmaceutski prihvatljive soli, te jedan ili više zajedničkih terapeutski djelotvornih sredstava.
14. Spoj prema bilo kojem od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da se upotrebljava kao lijek.
HRP20171999TT 2013-11-29 2014-11-28 Novi derivati aminopirimidina HRP20171999T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
PCT/IB2014/066422 WO2015079417A1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives
EP14821285.5A EP3074386B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HRP20171999T1 true HRP20171999T1 (hr) 2018-02-09

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Country Status (42)

Country Link
US (6) US9512084B2 (hr)
EP (5) EP4606377A3 (hr)
JP (2) JP6342495B2 (hr)
KR (2) KR102380539B1 (hr)
CN (2) CN110172056B (hr)
AP (1) AP2016009158A0 (hr)
AR (1) AR098549A1 (hr)
AU (1) AU2014356069B2 (hr)
BR (1) BR112016010397B1 (hr)
CA (1) CA2926908C (hr)
CL (1) CL2016001055A1 (hr)
CR (1) CR20160244A (hr)
CU (1) CU24384B1 (hr)
CY (3) CY1119705T1 (hr)
DK (3) DK3689865T3 (hr)
EA (1) EA031218B1 (hr)
EC (1) ECSP16054826A (hr)
ES (4) ES2947770T3 (hr)
FI (1) FI3689865T3 (hr)
HR (3) HRP20171999T1 (hr)
HU (3) HUE062248T2 (hr)
IL (1) IL244943B (hr)
JO (1) JO3314B1 (hr)
LT (3) LT3074386T (hr)
MA (1) MA39055B1 (hr)
MX (1) MX367911B (hr)
MY (2) MY179059A (hr)
NO (1) NO3074386T3 (hr)
NZ (1) NZ718835A (hr)
PE (1) PE20160869A1 (hr)
PH (1) PH12016500791A1 (hr)
PL (3) PL3074386T3 (hr)
PT (3) PT3689865T (hr)
RS (3) RS56657B1 (hr)
SI (3) SI3299368T1 (hr)
SV (1) SV2016005206A (hr)
TN (1) TN2016000128A1 (hr)
TW (1) TWI652261B (hr)
UA (1) UA117256C2 (hr)
UY (1) UY35858A (hr)
WO (1) WO2015079417A1 (hr)
ZA (1) ZA201602275B (hr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
JP6877339B2 (ja) 2014-10-14 2021-05-26 ノバルティス アーゲー Ｐｄ−ｌ１に対する抗体分子およびその使用
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
ES2876974T3 (es) * 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
MA46963A (fr) 2016-12-03 2019-10-09 Juno Therapeutics Inc Méthodes pour déterminer le dosage de céllules car-t
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
AU2019309727B2 (en) 2018-07-25 2021-12-23 Novartis Ag NLRP3 inflammasome inhibitors
MY206899A (en) 2018-08-29 2025-01-13 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
JP7742773B2 (ja) 2018-11-01 2025-09-22 ジュノー セラピューティクス インコーポレイテッド Ｇタンパク質共役受容体クラスｃグループ５メンバーｄ（ｇｐｒｃ５ｄ）に特異的なキメラ抗原受容体
EP3873943A2 (en) 2018-11-01 2021-09-08 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
AU2019381827A1 (en) 2018-11-16 2021-06-10 Juno Therapeutics, Inc. Methods of dosing engineered T cells for the treatment of B cell malignancies
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
MX2021014157A (es) * 2019-05-23 2022-01-04 Novartis Ag Formas cristalinas de un inhibidor btk.
LT3972603T (lt) * 2019-05-23 2024-12-10 Novartis Ag Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
EP3972604B1 (en) * 2019-05-23 2025-06-04 Novartis AG A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
WO2021133894A1 (en) * 2019-12-23 2021-07-01 Biogen Ma Inc. Btk inhibitors
CN115916223A (zh) 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
CR20230125A (es) 2020-08-14 2023-05-11 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
CA3208277A1 (en) * 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
KR20240055038A (ko) * 2021-09-03 2024-04-26 노파르티스 아게 다발성 경화증 치료를 위한 lou064
MX2024007354A (es) 2021-12-14 2024-06-28 Novartis Ag Metodos de tratamiento usando lou064.
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
TW202415644A (zh) 2022-09-30 2024-04-16 瑞士商諾華公司 合成方法及中間體
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
WO2025061148A1 (zh) * 2023-09-22 2025-03-27 江苏恒瑞医药股份有限公司 杂芳基类化合物、其制备方法及其在医药上的应用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2002236692A1 (en) 2000-10-23 2002-05-21 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase, their identification and use
RU2329263C2 (ru) 2000-11-07 2008-07-20 Новартис Аг Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
MXPA05006133A (es) 2002-12-09 2006-03-09 Univ Texas Metodos para inhibir selectivamente la tirosino quinasa jano 3 (jak3).
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
AR044402A1 (es) 2003-05-19 2005-09-14 Irm Llc Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
ES2543607T3 (es) 2005-03-10 2015-08-20 Gilead Connecticut, Inc. Ciertas amidas sustituidas, método de obtención, y método de su uso
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
ES2585902T3 (es) 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
WO2008110624A2 (en) 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano-Bicocca Sirna-mediated silencing of genes for treating chemotherapeutic drug-resistant epithelial tumors
JP5529852B2 (ja) 2008-05-06 2014-06-25 ジリード コネティカット，インコーポレイティド 置換アミド、その製造法及びＢｔｋインヒビターとしての使用
AU2009265813B2 (en) 2008-07-02 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
KR20120131171A (ko) * 2010-02-26 2012-12-04 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 치환된 알킬 그룹을 함유하는 티에노피리미딘
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN103889962B (zh) 2011-04-01 2017-05-03 犹他大学研究基金会 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
KR20190011343A (ko) 2011-06-10 2019-02-01 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
CA2840413A1 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
KR20140058543A (ko) 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
WO2013023084A2 (en) 2011-08-09 2013-02-14 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
WO2013083666A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
IN2012CH01573A (hr) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2014055928A2 (en) 2012-10-04 2014-04-10 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
KR102421388B1 (ko) 2022-07-18
SI3299368T1 (sl) 2020-07-31
IL244943A0 (en) 2016-05-31
US11673868B2 (en) 2023-06-13
US11180460B2 (en) 2021-11-23
MX2016006908A (es) 2016-08-17
JP6667573B2 (ja) 2020-03-18
PL3689865T3 (pl) 2023-07-31
CU20160078A7 (es) 2016-09-30
US20180251432A1 (en) 2018-09-06
CA2926908C (en) 2021-10-26
PE20160869A1 (es) 2016-09-08
DK3299368T3 (da) 2020-05-25
EP3689865B1 (en) 2023-03-29
CL2016001055A1 (es) 2016-10-28
ZA201602275B (en) 2017-08-30
ES3040769T3 (en) 2025-11-04
CA2926908A1 (en) 2015-06-04
ECSP16054826A (es) 2017-10-31
CN110172056B (zh) 2022-04-19
PT3074386T (pt) 2017-11-15
US20200010426A1 (en) 2020-01-09
BR112016010397B1 (pt) 2023-04-11
TW201609666A (zh) 2016-03-16
US20220041561A1 (en) 2022-02-10
HRP20200775T1 (hr) 2020-07-24
AR098549A1 (es) 2016-06-01
AU2014356069A1 (en) 2016-05-05
MY191381A (en) 2022-06-22
JP2018141005A (ja) 2018-09-13
US20160235746A1 (en) 2016-08-18
EP4606377A2 (en) 2025-08-27
RS60251B1 (sr) 2020-06-30
EA031218B1 (ru) 2018-12-28
AP2016009158A0 (en) 2016-04-30
HK1223368A1 (en) 2017-07-28
HUE037588T2 (hu) 2018-09-28
SI3074386T1 (en) 2018-02-28
JP6342495B2 (ja) 2018-06-13
EA201691125A1 (ru) 2016-09-30
ES2791525T3 (es) 2020-11-04
MY179059A (en) 2020-10-26
LT3074386T (lt) 2017-12-27
CR20160244A (es) 2016-07-29
EP3074386B1 (en) 2017-10-11
ES2655527T3 (es) 2018-02-20
LT3299368T (lt) 2020-05-25
DK3074386T3 (en) 2018-01-22
MX367911B (es) 2019-09-11
EP4219478B1 (en) 2025-06-11
TWI652261B (zh) 2019-03-01
PL3299368T3 (pl) 2020-08-10
CN110172056A (zh) 2019-08-27
EP3074386A1 (en) 2016-10-05
PL3074386T3 (pl) 2018-03-30
EP3299368A1 (en) 2018-03-28
UA117256C2 (uk) 2018-07-10
MA39055A1 (fr) 2018-02-28
ES2947770T3 (es) 2023-08-18
AU2014356069B2 (en) 2017-06-15
WO2015079417A1 (en) 2015-06-04
HUE049794T2 (hu) 2020-10-28
EP4606377A3 (en) 2025-11-26
CY1119705T1 (el) 2018-06-27
NO3074386T3 (hr) 2018-03-10
CN105683181A (zh) 2016-06-15
MA39055B1 (fr) 2018-10-31
PH12016500791B1 (en) 2016-06-13
LT3689865T (lt) 2023-07-10
RS64275B1 (sr) 2023-07-31
KR20160088877A (ko) 2016-07-26
US9512084B2 (en) 2016-12-06
KR102380539B1 (ko) 2022-03-29
CN105683181B (zh) 2019-04-23
US20230312483A1 (en) 2023-10-05
CU24384B1 (es) 2019-03-04
IL244943B (en) 2020-04-30
SI3689865T1 (sl) 2023-07-31
NZ718835A (en) 2021-12-24
RS56657B1 (sr) 2018-03-30
JP2016538313A (ja) 2016-12-08
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
CY1126056T1 (el) 2023-11-15
HK1252317A1 (en) 2019-05-24
KR20220044370A (ko) 2022-04-07
CY1122924T1 (el) 2021-10-29
US20150152068A1 (en) 2015-06-04
FI3689865T3 (fi) 2023-06-12
EP3299368B1 (en) 2020-02-26
HRP20230585T1 (hr) 2023-09-01
PT3689865T (pt) 2023-06-16
BR112016010397A8 (pt) 2020-04-22
PH12016500791A1 (en) 2016-06-13
HUE062248T2 (hu) 2023-10-28
TN2016000128A1 (en) 2017-10-06
UY35858A (es) 2015-06-30
PT3299368T (pt) 2020-05-28
DK3689865T3 (en) 2023-06-19
SV2016005206A (es) 2016-11-21
US10457647B2 (en) 2019-10-29
EP4219478A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
HRP20171999T1 (hr) Novi derivati aminopirimidina
HRP20160002T1 (hr) Bicikliäśki heterocikliäśki spojevi kao inhibitori protein tirozin kinaze
JP2016538313A5 (hr)
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
HRP20220255T1 (hr) Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izokinolina koji su korisni u liječenju raka
AR083339A1 (es) Compuestos de quinazolina como bloqueadores de los canales de sodio
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
AR058703A1 (es) Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
HRP20221043T1 (hr) Derivat oksi-fluoropiperidina kao inhibitor kinaze
SI2895174T1 (en) The prodrugs of the amino quinazoline kinase inhibitor
HRP20140953T1 (hr) Morfolino pirimidini i njihova uporaba za lijeäśenje
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
HRP20121069T1 (hr) Supstituirani derivati amida kao inhibitori protein kinaze
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
JP2016506962A5 (hr)
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
HRP20221207T1 (hr) Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5
EA200970655A1 (ru) 6-замещенные пиримидины, ингибирующие вич
ME02355B (me) Derivati 2-0ks0-1-pirolidinil imidazotiadiazola